Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 31, 2019. The Company is a biopharmaceutical entity focused on developing treatments for hepatitis C virus (HCV). The report details corporate governance changes and the termination of a strategic license agreement.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. However, it notes that as of the report date, no amounts were due to Emory University under the terminated License Agreement. The Company is currently evaluating whether the termination requires an impairment of intangible assets.
Material Changes
- Board Appointment: The Board appointed Mr. Todd Brady as a director and member of the Audit Committee, effective February 1, 2019. Mr. Brady was designated by principal stockholder Dr. Raymond Schinazi.
- License Termination: The Company notified Emory University on December 6, 2018, of the termination of their 2013 License Agreement covering HCV inhibitor patents. The Company no longer views these patents as essential to its HCV program.
- Strategic Focus: The Company continues to focus its HCV program on CC-31244, a Non-Nucleoside Polymerase Inhibitor currently in Phase 2a clinical trials.
Outlook, Risks, and Contingencies
The primary contingency identified is the potential impairment of intangible assets resulting from the termination of the Emory University License Agreement. The Company is actively evaluating the extent of this potential impairment. There are no reported related party transactions between the Company and the newly appointed director, Mr. Brady.
Investor Verification Checklist
- Verify the outcome of the Company's evaluation regarding the impairment of intangible assets related to the Emory University license termination.
- Monitor the progress of the CC-31244 Phase 2a clinical trial as the Company's primary HCV focus.
- Review future filings for any financial impact resulting from the asset impairment assessment.